{"downloaded": true, "htmlmade": false, "full": {"id": "30409796", "source": "MED", "pmid": "30409796", "pmcid": "PMC6442970", "fullTextIdList": {"fullTextId": "PMC6442970"}, "doi": "10.3324/haematol.2018.200014", "title": "The sympathomimetic agonist mirabegron did not lower <i>JAK2</i>-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14.", "authorString": "Drexler B, Passweg JR, Tzankov A, Bigler M, Theocharides AP, Cantoni N, Keller P, Stussi G, Ruefer A, Benz R, Favre G, Lundberg P, Nienhold R, Fuhrer A, Biaggi C, Manz MG, Bargetzi M, Mendez-Ferrer S, Skoda RC, Swiss Group for Clinical Cancer Research (SAKK).", "authorList": {"author": [{"fullName": "Drexler B", "firstName": "Beatrice", "lastName": "Drexler", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, University Hospital Basel and University of Basel, Switzerland."}}}, {"fullName": "Passweg JR", "firstName": "Jakob R", "lastName": "Passweg", "initials": "JR", "authorId": {"@type": "ORCID", "#text": "0000-0001-7092-3351"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, University Hospital Basel and University of Basel, Switzerland jakob.passweg@usb.ch."}}}, {"fullName": "Tzankov A", "firstName": "Alexandar", "lastName": "Tzankov", "initials": "A", "authorId": {"@type": "ORCID", "#text": "0000-0002-1100-3819"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Institute of Pathology, University Hospital Basel and University of Basel, Switzerland."}}}, {"fullName": "Bigler M", "firstName": "Martin", "lastName": "Bigler", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Swiss Group for Clinical Cancer Research, Bern, Switzerland."}}}, {"fullName": "Theocharides AP", "firstName": "Alexandre Pa", "lastName": "Theocharides", "initials": "AP", "authorId": {"@type": "ORCID", "#text": "0000-0002-1535-8692"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology and Oncology, University Hospital Zurich and University of Zurich, Switzerland."}}}, {"fullName": "Cantoni N", "firstName": "Nathan", "lastName": "Cantoni", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Oncology, Hematology & Transfusion Medicine, Kantonsspital Aarau AG, Switzerland."}}}, {"fullName": "Keller P", "firstName": "Peter", "lastName": "Keller", "initials": "P", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University Clinic of Hematology and Central Hematology Laboratory, University Hospital Bern, Switzerland."}}}, {"fullName": "Stussi G", "firstName": "Georg", "lastName": "Stussi", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Clinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland."}}}, {"fullName": "Ruefer A", "firstName": "Axel", "lastName": "Ruefer", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Departement Medizin, Luzerner Kantonsspital, Switzerland."}}}, {"fullName": "Benz R", "firstName": "Rudolf", "lastName": "Benz", "initials": "R", "authorId": {"@type": "ORCID", "#text": "0000-0001-8198-6454"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Kantonsspital Muensterlingen, Switzerland."}}}, {"fullName": "Favre G", "firstName": "Genevi\u00e8ve", "lastName": "Favre", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Cantonal Hospital Liestal, Switzerland."}}}, {"fullName": "Lundberg P", "firstName": "Pontus", "lastName": "Lundberg", "initials": "P", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, University Hospital Basel and University of Basel, Switzerland."}}}, {"fullName": "Nienhold R", "firstName": "Ronny", "lastName": "Nienhold", "initials": "R", "authorId": {"@type": "ORCID", "#text": "0000-0001-5057-430X"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Switzerland."}}}, {"fullName": "Fuhrer A", "firstName": "Andrea", "lastName": "Fuhrer", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Swiss Group for Clinical Cancer Research, Bern, Switzerland."}}}, {"fullName": "Biaggi C", "firstName": "Christine", "lastName": "Biaggi", "initials": "C", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Swiss Group for Clinical Cancer Research, Bern, Switzerland."}}}, {"fullName": "Manz MG", "firstName": "Markus G", "lastName": "Manz", "initials": "MG", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology and Oncology, University Hospital Zurich and University of Zurich, Switzerland."}}}, {"fullName": "Bargetzi M", "firstName": "Mario", "lastName": "Bargetzi", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Oncology, Hematology & Transfusion Medicine, Kantonsspital Aarau AG, Switzerland."}}}, {"fullName": "Mendez-Ferrer S", "firstName": "Simon", "lastName": "Mendez-Ferrer", "initials": "S", "authorId": {"@type": "ORCID", "#text": "0000-0002-9805-9988"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Department of Haematology, University of Cambridge, and National Health Service Blood and Transplant, Cambridge, UK."}}}, {"fullName": "Skoda RC", "firstName": "Radek C", "lastName": "Skoda", "initials": "RC", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Switzerland radek.skoda@unibas.ch."}}}, {"collectiveName": "Swiss Group for Clinical Cancer Research (SAKK)"}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0001-5057-430X"}, {"@type": "ORCID", "#text": "0000-0001-7092-3351"}, {"@type": "ORCID", "#text": "0000-0001-8198-6454"}, {"@type": "ORCID", "#text": "0000-0002-1100-3819"}, {"@type": "ORCID", "#text": "0000-0002-1535-8692"}, {"@type": "ORCID", "#text": "0000-0002-9805-9988"}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "4", "volume": "104", "journalIssueId": "2798999", "dateOfPublication": "2019 Apr", "monthOfPublication": "4", "yearOfPublication": "2019", "printPublicationDate": "2019-04-01", "journal": {"title": "Haematologica", "ISOAbbreviation": "Haematologica", "medlineAbbreviation": "Haematologica", "NLMid": "0417435", "ISSN": "0390-6078", "ESSN": "1592-8721"}}, "pubYear": "2019", "pageInfo": "710-716", "abstractText": "The \u03b2-3 sympathomimetic agonist BRL37344 restored nestin-positive cells within the stem cell niche, and thereby normalized blood counts and improved myelofibrosis in a mouse model of <i>JAK2</i>-V617F-positive myeloproliferative neoplasms. We therefore tested the effectiveness of mirabegron, a \u03b2-3 sympathomimetic agonist, in a phase II trial including 39 <i>JAK2</i>-V617F-positive patients with myeloproliferative neoplasms and a mutant allele burden more than 20%. Treatment consisted of mirabegron 50 mg daily for 24 weeks. The primary end point was reduction of <i>JAK2</i>-V617F allele burden of 50% or over, but this was not reached in any of the patients. One patient achieved a 25% reduction in <i>JAK2</i>-V617F allele burden by 24 weeks. A small subgroup of patients showed hematologic improvement. As a side study, bone marrow biopsies were evaluated in 20 patients. We found an increase in the nestin<sup>+</sup> cells from a median of 1.09 (interquartile range 0.38-3.27)/mm<sup>2</sup> to 3.95 (interquartile range 1.98-8.79)/mm<sup>2</sup> (<i>P</i><0.0001) and a slight decrease of reticulin fibrosis from a median grade of 1.0 (interquartile range 0-3) to 0.5 (interquartile range 0-2) (<i>P</i>=0.01) between start and end of mirabegron treatment. Despite the fact that the primary end point of reducing <i>JAK2</i>-V617F allele burden was not reached, the observed effects on nestin<sup>+</sup> mesenchymal stem cells and reticulin fibrosis is encouraging, and shows that mirabegron can modify the microenvironment where the <i>JAK2</i>-mutant stem cells are maintained. (Registered at <i>clinicaltrials.gov identifier: 02311569</i>).", "affiliation": "Division of Hematology, University Hospital Basel and University of Basel, Switzerland.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Journal Article"]}, "grantsList": {"grant": [{"grantId": "MC_PC_12009", "agency": "Medical Research Council", "orderIn": "0"}, {"grantId": "648765", "agency": "European Research Council", "orderIn": "0"}, {"grantId": "26670", "agency": "Cancer Research UK", "acronym": "CRUK_", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Animals"}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Mice"}, {"majorTopic_YN": "Y", "descriptorName": "Hematologic Neoplasms", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "N"}, {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "Y", "descriptorName": "Myeloproliferative Disorders", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "N"}, {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Fibrosis"}, {"majorTopic_YN": "N", "descriptorName": "Acetanilides", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Thiazoles", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "Y", "descriptorName": "Reticulin", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Sympathomimetics", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Amino Acid Substitution"}, {"majorTopic_YN": "Y", "descriptorName": "Mutation, Missense"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "Y", "descriptorName": "Janus Kinase 2", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "Y", "descriptorName": "Nestin", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}]}, "chemicalList": {"chemical": [{"name": "nestin", "registryNumber": "0"}, {"name": "Sympathomimetics", "registryNumber": "0"}, {"name": "Thiazoles", "registryNumber": "0"}, {"name": "Acetanilides", "registryNumber": "0"}, {"name": "Reticulin", "registryNumber": "0"}, {"name": "JAK2 protein, human", "registryNumber": "EC 2.7.10.2"}, {"name": "Janus Kinase 2", "registryNumber": "EC 2.7.10.2"}, {"name": "mirabegron", "registryNumber": "MVR3JL3B2V"}, {"name": "NES protein, human", "registryNumber": "0"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.3324/haematol.2018.200014"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6442970"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6442970?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "13", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by-nc", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "N", "dateOfCompletion": "2020-05-06", "dateOfCreation": "2018-11-10", "firstIndexDate": "2018-11-10", "fullTextReceivedDate": "2020-07-14", "dateOfRevision": "2020-05-06", "electronicPublicationDate": "2018-11-08", "firstPublicationDate": "2018-11-08"}, "htmllinks": "https://europepmc.org/articles/PMC6442970", "abstract": "The \u03b2-3 sympathomimetic agonist BRL37344 restored nestin-positive cells within the stem cell niche, and thereby normalized blood counts and improved myelofibrosis in a mouse model of <i>JAK2</i>-V617F-positive myeloproliferative neoplasms. We therefore tested the effectiveness of mirabegron, a \u03b2-3 sympathomimetic agonist, in a phase II trial including 39 <i>JAK2</i>-V617F-positive patients with myeloproliferative neoplasms and a mutant allele burden more than 20%. Treatment consisted of mirabegron 50 mg daily for 24 weeks. The primary end point was reduction of <i>JAK2</i>-V617F allele burden of 50% or over, but this was not reached in any of the patients. One patient achieved a 25% reduction in <i>JAK2</i>-V617F allele burden by 24 weeks. A small subgroup of patients showed hematologic improvement. As a side study, bone marrow biopsies were evaluated in 20 patients. We found an increase in the nestin<sup>+</sup> cells from a median of 1.09 (interquartile range 0.38-3.27)/mm<sup>2</sup> to 3.95 (interquartile range 1.98-8.79)/mm<sup>2</sup> (<i>P</i><0.0001) and a slight decrease of reticulin fibrosis from a median grade of 1.0 (interquartile range 0-3) to 0.5 (interquartile range 0-2) (<i>P</i>=0.01) between start and end of mirabegron treatment. Despite the fact that the primary end point of reducing <i>JAK2</i>-V617F allele burden was not reached, the observed effects on nestin<sup>+</sup> mesenchymal stem cells and reticulin fibrosis is encouraging, and shows that mirabegron can modify the microenvironment where the <i>JAK2</i>-mutant stem cells are maintained. (Registered at <i>clinicaltrials.gov identifier: 02311569</i>).", "pdflinks": "https://europepmc.org/articles/PMC6442970?pdf=render", "journaltitle": "Haematologica", "title": "The sympathomimetic agonist mirabegron did not lower <i>JAK2</i>-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14."}